ERBB2 and glioblastoma: For the treatment of GBM, promising results have been reported in clinical studies using CAR-T cells that target the epidermal growth factor receptor variant III (EGFRvIII), interleukin 13 receptor subunit alpha 2 (IL13Rα2), or human epidermal growth factor receptor 2 (HER2) [8–10].